By
Great Basin Corporation
Published: July 3, 2012, 4:57 p.m.·
Tags:
None
Great Basin Corporation, a privately-held molecular diagnostics company developing sample-to-result solutions, announced today that a study published in the July issue of the Journal of Clinical Microbiology demonstrates its TB ID/R assay to be 96 percent accurate in detecting rifampin-resistant Mycobacterium tuberculosis (TB). The assay is currently under development to provide rapid diagnosis and drug susceptibility information for TB.
Read More →